The anti-tumor activity of disulfiram was limited in CIPp cells with overexpressed MUC1, along with little interference of disulfiram on the activation of PI3K/Akt/mTOR, indicating that the level of MUC1 affected the efficiency of disulfiram in treating canine mammary tumors. The gene discussed is MTOR; the disease is breast cancer.